herp
simplex
viru
type
sexual
transmit
pathogen
infect
oral
genit
mucosa
human
signific
caus
morbid
worldwid
mous
vagin
model
infect
develop
sever
investig
although
degre
pathogen
viru
mice
depend
viru
strain
use
gener
experiment
infect
vagin
rout
iv
result
neurolog
diseas
preced
easili
recogniz
symptom
due
inflamm
follow
rear
leg
paralysi
death
mous
model
provid
use
tool
test
effect
antivir
infect
mani
studi
perform
laboratori
antivir
compound
isol
leav
melia
azedarach
l
name
meliacin
shown
meliacin
strongli
inhibit
replic
vero
cell
exhibit
synergist
antivir
activ
combin
acyclovir
studi
perform
et
al
suggest
exert
antivir
action
synthesi
viral
dna
matur
progress
vero
cell
vivo
studi
shown
meliacin
prevent
develop
stromal
kerat
mice
likewis
sever
herpet
infect
femal
mice
infect
intravagin
also
amelior
treatment
hand
besid
broad
effect
antivir
action
meliacin
act
immunomodul
vitro
agent
inhibit
phagocytosi
opson
sheep
erythrocyt
impair
prolifer
spleen
lymph
node
cell
moreov
meliacin
weak
induc
tumor
necrosi
factor
alpha
murin
macrophag
cultur
caus
synergist
effect
product
induc
lp
vagin
wash
femal
mice
infect
iv
treat
meliacin
contain
increas
amount
comparison
infect
nontreat
anim
ifn
respons
repres
earli
host
defens
event
one
occur
prior
onset
immun
respons
context
macrophag
play
central
role
resist
mice
primari
infect
mainli
sourc
antivir
cytokin
ifn
produc
rapidli
infect
strong
activ
macrophag
produc
earli
stage
infect
natur
killer
cell
later
stage
activ
cell
innat
immun
respons
viral
infect
depend
integr
network
cytokin
tightli
regul
vivo
situat
led
us
queri
whether
administr
meliacin
infect
mice
could
alter
homoestasi
ifn
host
respons
either
affect
antivir
activ
ifn
synerg
interact
answer
question
conduct
experi
follow
indirect
approach
base
observ
synerg
ifn
inhibit
replic
vero
cell
end
vero
cell
infect
treat
combin
presenc
absenc
meliacin
differ
experiment
condit
perform
experi
instead
meliacin
work
compound
cdm
molecul
respons
broad
spectrum
meliacin
antivir
action
summari
analyz
suscept
combin
vero
cell
sinc
publish
data
avail
herpesviru
ii
effect
cdm
interferon
action
sinc
publish
data
effect
ifn
infect
vero
cell
capac
human
andor
inhibit
replic
strain
ms
g
initi
perform
plaqu
reduct
assay
concentr
use
present
experi
previous
test
ko
strain
vero
cell
pretreat
hour
iuml
ifn
separ
combin
infect
ms
g
strain
moi
pfu
per
cell
ko
f
strain
also
test
use
moi
serv
control
effici
strain
ko
f
plaqu
format
quit
modestli
reduc
presenc
alon
wherea
combin
act
synergist
previous
report
simultan
treatment
vero
cell
reduc
plaqu
format
fold
ms
strain
fold
g
strain
comparison
effect
ifn
alon
tabl
likewis
level
inhibit
achiev
combin
treatment
consequ
doubl
amount
ifn
per
cultur
seen
tabl
increas
concentr
ifn
iuml
augment
inhibitori
effect
result
indic
replic
vero
cell
member
herp
viru
famili
like
vzv
cmv
show
increas
suscept
ifn
combin
respect
ifn
alon
character
inhibitori
effect
treatment
replic
three
day
viral
growth
assay
perform
vero
cell
pretreat
h
iuml
ifn
separ
combin
cell
infect
ms
g
strain
moi
pfu
per
cell
cultur
supernat
harvest
h
pi
titer
infecti
viru
control
purpos
strain
ko
f
similarli
treat
includ
accord
result
present
tabl
observ
greater
inhibitori
effect
replic
vero
cultur
treat
ifn
combin
alon
despit
interferon
show
greater
antivir
activ
plaqu
reduct
assay
figur
cultur
treat
iuml
ms
g
replic
reduc
respect
p
h
pi
figur
h
pi
viral
titer
cultur
approach
level
detect
vehicletr
group
howev
rel
vehicl
control
cultur
viral
titer
recov
h
cultur
treat
reduc
msinfect
cultur
g
infect
cultur
respect
figur
infect
cultur
treat
combin
inhibitori
effect
differ
strain
titer
ms
reduc
approxim
rel
vehicl
treat
vero
cell
time
point
test
case
g
ifn
combin
viru
titer
reduc
comparison
control
cultur
h
pi
h
pi
antivir
activ
decreas
howev
viru
replic
still
inhibit
result
indic
combin
synerg
antivir
effect
similar
mode
previous
report
figur
due
long
time
ifn
contact
cell
experi
describ
perform
new
one
order
discard
cytotox
due
cytokin
could
affect
result
observ
purpos
cultur
vero
cell
treat
h
combin
time
monolay
infect
pfu
per
cell
ms
strain
fresh
medium
contain
ifn
ad
h
viru
adsorpt
remain
end
experi
cell
morpholog
observ
light
microscop
number
viabl
cell
h
pi
determin
mtt
colorimetr
assay
comparison
vehicl
treat
uninfect
cell
ifn
treatment
affect
cell
morpholog
prolifer
figur
infect
ms
strain
destroy
vehicletr
cell
h
pi
figur
treatment
delay
onset
cpe
msinfect
cultur
increas
fraction
viabl
cell
recov
h
pi
figur
howev
h
pi
cultur
appear
like
vehicl
treat
cell
contrast
combin
provid
greatest
protect
msinfect
cell
remain
viabl
h
pi
figur
result
experi
support
previou
find
tabl
figur
combin
inhibit
replic
vero
cell
synergist
manner
order
investig
whether
cdm
could
interact
cytokin
antivir
effect
vero
cell
perform
sever
experi
first
test
effect
cdm
cell
cpe
protect
provid
combin
purpos
experi
similar
describ
figur
perform
presenc
cdm
number
surviv
cell
determin
h
pi
figur
comparison
figur
show
presenc
cdm
alon
vero
cell
highli
protect
cytopath
sinc
infect
cell
remain
viabl
cdm
combin
number
protect
cell
increas
respect
effect
interferon
alon
suggest
protect
observ
due
cdm
effect
interestingli
cell
treat
cdm
plu
ifn
combin
seem
addit
antivir
effect
phenomenon
confirm
next
experi
also
test
presenc
cdm
differ
experiment
condit
could
affect
antivir
action
ifn
ms
replic
viru
yield
h
pi
determin
vero
cell
treat
cdm
follow
h
prior
interferon
induct
remov
ii
ad
simultan
ifn
remain
h
infect
iii
ad
viru
infect
remain
viru
harvest
iiii
ad
ifn
h
infect
read
infect
remain
viru
harvest
result
obtain
follow
protocol
depict
figur
antivir
effect
due
interferon
alon
combin
increas
cell
pretreat
cdm
indic
cdm
treatment
interfer
antivir
activ
display
ifn
alon
combin
contrari
specul
antivir
effect
cdm
alon
contribut
addit
manner
overal
antivir
activ
cdm
present
h
ifn
antivir
induct
period
interpret
result
rather
complic
antivir
effect
cdm
per
se
reduc
replic
figur
likewis
experi
describ
figur
addit
effect
cdm
cell
treat
combin
figur
cdm
ad
viru
infect
remain
h
pi
also
present
induct
period
antivir
effect
compound
high
reduct
viru
yield
respect
mask
interact
ifn
figur
reason
repeat
experi
shown
figur
lower
concentr
cdm
viru
yield
h
pi
cultur
treat
cdm
cdm
plu
iuml
cdm
plu
iuml
determin
seen
figur
cdm
alon
inhibit
viru
replic
dose
depend
manner
combin
ifn
cdm
increas
log
antivir
effect
without
alter
kinet
inhibit
observ
result
suggest
presenc
cdm
interfer
inhibit
alon
combin
bind
specif
cell
receptor
modifi
transcript
translat
environ
antivir
state
induc
howev
nearli
anim
virus
evolv
mechan
antagon
effect
ifninduc
antivir
state
case
report
resist
activ
process
depend
express
least
two
viral
protein
immedi
earli
protein
express
also
play
role
resist
thu
explain
alon
weak
inhibitor
wild
type
viru
replic
strikingli
recent
studi
show
coactiv
receptor
render
cell
highli
resist
replic
find
turn
gener
phenomenon
sinc
synergist
antivir
effect
combin
ifn
also
demonstr
member
herpesvirida
varieti
rna
virus
like
sar
lassa
viru
hcv
consid
background
current
investig
undertaken
determin
ifn
combin
inhibit
synergist
manner
replic
vero
cell
determin
presenc
plant
deriv
antivir
compound
cdm
could
affect
antivir
state
induc
combin
expect
result
shown
tabl
figur
figur
clearli
demonstr
plaqu
format
viral
replic
onset
viral
cpe
vero
cell
synergist
inhibit
interferon
combin
wherea
individu
cytokin
weak
induc
antivir
respons
independ
concentr
tri
iu
tabl
importantli
evid
two
cytokin
individu
collect
harm
uninfect
infect
cell
concentr
use
figur
contrari
cell
remain
viabl
cytokin
exposur
h
induct
period
assess
mtt
exclus
colorimetr
method
remain
abl
prolifer
figur
indic
viru
inhibit
consequ
blockad
viru
replic
host
cell
death
valid
find
provid
inclus
ko
f
strain
experi
control
result
depict
tabl
figur
ko
h
f
show
synergist
effect
ifn
combin
viru
replic
confirm
previou
studi
antivir
effect
cdm
infect
cell
due
alter
cellular
process
work
vsv
model
system
demonstr
cdm
exert
antivir
action
endocyt
exocyt
pathway
vsv
pre
posttreat
effect
consequ
cdm
induc
cytoplasm
alkalin
intracellular
endosom
refractori
state
viru
infect
reach
maximum
h
pretreat
fulli
maintain
h
later
howev
even
h
cell
still
remain
partial
resist
viru
infect
sinc
acidif
vacuolar
compart
play
import
role
varieti
cellular
process
wonder
presenc
cdm
could
inhibit
antivir
state
induc
interferon
treatment
result
present
figur
show
concentr
cdm
alon
combin
interferon
affect
uninfect
cell
viabil
moreov
presenc
cdm
either
alon
combin
h
figur
contribut
protect
cell
viru
cpe
result
obtain
perturb
compound
cytopath
test
antivir
action
ifn
use
standard
procedur
compris
period
h
cell
treatment
induct
antivir
state
previou
viru
infect
ifn
remov
viru
adsorpt
read
viru
harvest
presenc
cdm
h
induct
h
induct
period
h
infect
complet
ifn
treatment
period
affect
ifn
action
contrari
presenc
cdm
enhanc
effect
antivir
action
interferon
alon
combin
see
figur
observ
indic
alter
cellular
process
occur
cell
exposur
cdm
interfer
establish
refractori
stage
infect
cell
treat
ifn
remark
sensit
cdm
increas
steadili
accord
time
cell
treatment
thu
h
pretreat
cdm
viru
titer
fold
reduc
figur
pretreat
extend
h
viru
reduct
increas
time
figur
accord
previou
result
obtain
meliacin
addit
cdm
cell
infect
caus
strong
inhibit
viru
titer
order
fold
figur
unexpectedli
cdm
present
h
infect
h
afterward
viru
yield
reduc
time
figur
high
antivir
activ
cdm
per
se
complic
interpret
result
obtain
presenc
ifn
figur
comparison
reduc
amount
viru
even
combin
less
log
overcom
inconveni
perform
experi
lower
concentr
cdm
ad
viru
infect
last
viru
harvest
combin
iuml
clear
addit
effect
cdm
cdm
plu
concentr
test
observ
figur
thu
result
report
indic
presenc
cdm
alter
biolog
activ
combin
result
envis
administr
cdm
vivo
could
affect
product
ifn
import
mediat
innat
resist
infect
shown
togeth
synergist
inhibit
replic
vitro
like
also
demonstr
other
dna
rna
virus
hand
shown
cdm
display
high
antivir
activ
without
interf
biolog
activ
ifn
hypothes
vivo
administr
cdm
could
affect
antivir
activ
interferon
inhibit
replic
mice
genit
tract
vero
cell
grown
eagl
minimum
essenti
medium
supplement
inactiv
calf
serum
mem
gentamycin
maintain
monolay
format
mem
supplement
inactiv
calf
serum
mem
wild
type
ko
strain
gift
dr
erik
de
clercq
rega
institut
leuven
belgium
strain
f
strain
ms
g
obtain
american
type
cultur
collect
propag
vero
cell
recombin
human
b
sidu
bueno
air
argentina
interferongamma
boehring
ingelheim
ingelheim
germani
ad
cultur
h
infect
replac
hsv
infect
maintain
supernat
harvest
experi
iuml
interferon
use
unless
state
otherwis
cdm
purifi
laboratori
leav
mazedarach
l
describ
et
al
solubil
mem
final
concentr
mgml
store
cdm
use
concentr
plaqu
reduct
assay
vero
cell
seed
plate
densiti
cell
per
well
h
later
iuml
iuml
ad
cultur
medium
vero
cell
inocul
strain
ms
g
strain
ko
f
h
later
adsorpt
medium
replac
complet
mem
contain
methylcellulos
ifn
use
pretreat
plaqu
count
two
day
later
viru
replic
assay
vero
cell
seed
plate
densiti
cell
per
well
h
later
cultur
treat
vehicl
iuml
andor
iuml
h
ifn
treatment
cell
monolay
inocul
strain
ms
g
strain
ko
f
multipl
infect
moi
pfu
per
cell
h
adsorpt
inoculum
remov
fresh
ifncontain
cultur
medium
return
well
twentyfour
h
pi
titer
infecti
viru
cell
supernat
determin
serial
dilut
plaqu
assay
vero
cell
test
effect
cdm
ifn
antivir
action
perform
differ
experiment
schedul
vero
cell
treat
cdm
follow
h
prior
interferon
induct
remov
ii
ad
simultan
ifn
remain
h
infect
iii
ad
viru
infect
remain
viru
harvest
iiii
ad
ifn
h
infect
read
infect
remain
viru
harvest
vero
cell
establish
densiti
cellswel
plate
h
later
fresh
cultur
medium
medium
contain
cdm
iuml
iuml
alon
combin
cdm
ad
cultur
medium
vero
cell
inocul
ms
ko
h
later
viru
adsorpt
medium
replac
fresh
cultur
medium
contain
ifn
concentr
use
pretreat
h
pi
cell
morpholog
observ
light
microscop
cell
viabil
determin
describ
previous
use
cleavag
tetrazolium
salt
mtt
tetrazolium
bromid
sigma
mitochondri
enzym
succin
dehydrogenas
give
blue
product
formazan
absorb
well
measur
eurogenet
mpra
micropl
reader
use
test
wavelength
nm
refer
wavelength
nm
number
surviv
cell
determin
interpol
standard
calibr
curv
correl
optic
densiti
valu
number
viabl
cell
determin
count
haemocytomet
data
present
mean
standard
error
mean
sem
data
ifntreat
group
compar
vehicletr
group
signific
differ
determin
oneway
analysi
varianc
anova
follow
turkey
post
hoc
test
graphpad
home
san
diego
ca
author
declar
compet
interest
ep
particip
experiment
design
perform
experi
draft
manuscript
cec
conceiv
design
studi
draft
manuscript
author
read
approv
final
manuscript
